GLP‑1 and ghrelin signal trouble

Hunger and fullness are controlled by gut hormones, and obesity can disrupt those signals before a person makes a single food choice. (ncbi.nlm.nih.gov) One hormone, ghrelin, rises before meals and pushes the brain toward hunger. Another, glucagon-like peptide 1, or GLP-1, is released after eating and helps create the feeling that a meal was enough. (ncbi.nlm.nih.gov) Researchers describe those hormones as part of a gut-brain system that helps regulate appetite, food reward, insulin release, and body weight. Reviews in 2024 and 2025 said obesity is often linked to lower fasting or meal-related satiety signals and altered hunger signaling rather than a simple failure of willpower. (nature.com) (pmc.ncbi.nlm.nih.gov) That framing has moved from specialist journals into everyday medicine because glucagon-like peptide 1 drugs are now widely used for both type 2 diabetes and obesity. A New England Journal of Medicine review published in April 2026 said these medicines work in part by suppressing appetite through brain and gut pathways. (nejm.org) The medical context is large: the Centers for Disease Control and Prevention says adult obesity prevalence exceeded 35% in 23 states in 2023, and national survey data for August 2021 through August 2023 found about 40.3% of United States adults had obesity. (cdc.gov) (ncbi.nlm.nih.gov) The World Health Organization said in its December 8, 2025 fact sheet that 890 million adults worldwide were living with obesity in 2022. The agency described obesity as a chronic disease shaped by diet, physical activity, genetics, environment, and other factors. (who.int) The biology is not as simple as “ghrelin bad, GLP-1 good.” A 2021 review said the two signals act like opposing messages in the gut-brain axis, affecting not only hunger and satiety but also how strongly food cues and rewards pull behavior. (pmc.ncbi.nlm.nih.gov) Scientists are also trying to separate fullness from side effects. A 2024 Nature study mapped brain circuits for glucagon-like peptide 1 receptor signaling and found satiety and aversion could be dissociable, a result that could shape future obesity drugs. (nature.com) Weight loss itself can push these signals around. A meta-analysis published in February 2025 found that after weight loss, appetite-related hormone changes may reflect a physiological adaptation that can favor weight regain. (nature.com) Clinical guidance has started to reflect that shift in language. The National Institute for Health and Care Excellence updated its overweight and obesity guideline on January 8, 2026 and told clinicians to use tailored, respectful care rather than treating weight as a simple matter of personal choice. (nice.org.uk) The bottom line is that appetite is regulated by chemistry as well as behavior, and modern obesity care increasingly treats disrupted hunger and fullness signals as part of the disease itself. (who.int) (nice.org.uk)